최원석 교수는 2002년에 고려대학교 의과대학을 졸업하고 동대학의 대학원에서 석사, 박사 학위를 취득하였다. 2009년 고려대학교 의과대학 내과학교실 감염내과에 조교수로 발령 받았으며, 현재 부교수로 재직 중이다. 최원석 교수는 내과전문의, 감염내과 분과전문의, 중환자의학 세부전문의 자격을 가지고 있으며, 고려대학교 의료원 안산병원 감염내과에서 외래 및 입원 환자에 대한 진료를 하고 있다. 최원석 교수의 진료 분야는 감염질환의 진단과 치료, 불명열의 진단, 성인예방접종에 대한 상담 및 접종 등이다. 최원석 교수는 다양한 연구를 수행하고 있으며 주요 연구 분야는 인플루엔자, 대상포진 등 감염질환의 역학(epidemiology), 백신(vaccine), 감염질환의 감시 및 관리(surveillance and control of infectious diseases)이다.

Education

• 1996 - 2002: Korea University College of Medicine, Seoul, Korea: M.D.
• 2004 - 2006: Korea University Graduate School, Seoul, Korea: M.Sc.
• 2006 - 2009: Korea University Graduate School, Seoul, Korea: Ph.D.

Professional Experiences

• 2002-2003: Internship in Korea University Medical Center, Seoul
• 2003-2007: Residency in Internal Medicine, Korea University Hospital, Seoul
• 2007-2008: Senior researcher in Division of Vaccine Preventable Disease Control & National Immunization Program, Center of Disease Prevention, Korea Center for Disease Control and Prevention
• 2008-2009: Fellow in Division of Infectious Disease, Department of Internal Medicine, Korea University Medical Center Guro Hospital
• 2009-2011: Lecturer in Division of Infectious Disease, Department of Internal Medicine, Korea University Medical Center Ansan Hospital
• 2009-2011: Adjunct Professor in Korea University College of Medicine
• 2011-2016: Assistant Professor in Korea University College of Medicine, Korea University Medical Center Ansan Hospital
• 2014-2017: Expert Secretary of Institutional Review Board of Korea University Ansan Hospital
• 2014-2017: Vice Director of Referral Center of Korea University Ansan Hospital
• 2017-2018: Visiting scholar in the University of Pittsburgh
• 2017-2017: Member of Expert Committee on Vaccine Injury Compensation of KCDC
• 2012-Now: Member of Committee on Adult Immunization of Korean Society of Infectious Diseases
• 2013-Now: Member of Subcommittees of Korea Advisory Committee on Immunization Practice of Korea Center for Diseases Control and Prevention (KCDC)
• 2015-Now: Member of Cooperation Committee for Infectious Disease Control in Gyeonggi-do
• 2016-Now: Advisory Member of Gyenggi Infectious Disease Conrol Center (GIDCC)
• 2016-Now: Associate Professor in Korea University College of Medicine, Korea University Medical Center Ansan Hospital
• 2017-Now: Private expert of Immediate Response Team of KCDC

Specialty certification

• Certificate of Medical Doctor, Ministry of Health and Welfare
• Certified Board of Internal Medicine, Korean Board of Internal Medicine
• Certified Subspecialty Board of Infectious Disease, Korean Board of Internal Medicine
• Certified Subspecialty Board of Critical Care Medicine, Korean Academy of Medical Science

Membership

• Member of Korean Medical Association
• Member of Korean Association of Internal Medicine
• Member of Korean Society of Infectious Diseases
• Member of Korean Society for Chemotherapy
• Member of Korean Society for Nosocomial Infection Control
• Member of Korean Society of Critical Care Medicine

Research career as a principal investigator

• 1. A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER (2017~2017)
• 2. Development of long-term strategy for national immunization program in the Republic of Korea. Korea Center for Disease Control and Prevention
• 3. A Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of CT-P27 in Subjects with Acute Uncomplicated Influenza A Infection (2016~2017)
• 4. A Study to Explore the Distribution of Influenza, RSV and hMPV in Adults Hospitalized with Acute Respiratory Tract Infection (2016~ 2017)
• 5. A Multi-center, Randomized, Double blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and over (2015—2017)
• 6. Operation of pilot project for infectious diseases surveillance system in Gyeonggi-do
• 7. A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study to Investigate the Efficacy (Immunogenicity) and Safety of GC3106 (quadrivalent cell-culture based influenza vaccine) after Intramuscular Administration in Healthy Subjects (2015—2016)
• 8. Multicenter, Open, Non-comparative, Phase III Study to Evaluate the Immunogenicity and Safety of 'Hantavax' in Healthy Adult (2015—present)
• 9. Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Subjects aged 18 to 60 years in the Republic of Korea (2015—2016)
• 10. A phase 3, multicenter, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IV and oral delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections (2014 – 2015).
• 11. A randomized, double-blind, multi-center study to evaluate the efficacy and safety of intravenous to oral solithromycin compared to intravenous to oral moxifloxacin in the treatment of adult patients with community-acquired bacterial pneumonia (2014-2015).
• 12. Phase III clinical trial to assess the immunogenicity and safety of ‘NBP-607-QIV(quadrivalent inactivated cell culture-derived influenza vaccine)’ compared to trivalent inactivated cell culture-derived influenza vaccine in adults and elderly subjects (2014-2015).
• 13. A multicenter, randomized, double-blind, active-controlled, parallel phase III study to investigate the efficacy (immunogenicity) and safety of GC3110A (quadrivalent influenza vaccine) after intramuscular administration in healthy subjects (2014-2015).
• 14. A multi-center, randomized, double-blind phase III clinical trial to assess the immunogenicity and safety of ‘NBP607 (trivalent inactivated cell culture-derived influenza vaccine)’ in healthy adults and elderly subjects (2013-2014).
• 15. A multi-center, randomized, double-blind phase III clinical trial to assess the immunogenicity and safety of NBP608 compared to zostavax in healthy adults aged 50 and over (2013-2015).
• 16. A randomized, double-blinded, active-controlled study of CB-183,315 in patients with Clostridium difficile associated diarrhea (2013-2015).
• 17. Efficacy, immunogenicity, and safety study of Clostridium difficile toxoid vaccine in subjects at risk for C. difficile infection (2013-2018).
• 18. Phase III, randomized, multicenter, double-blind, double-dummy, parallel-group comparative study to determine the efficacy, safety and tolerability of ceftazidime-avibactam (CAZ-AVI) versus meropenem in the treatment of nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP) in hospitalized adults (2013-2015).
• 19. A phase III, randomized, multicenter, double-blind, double-dummy, parallel-group, comparative study to determine the efficacy, safety, and tolerability of ceftazidime avibactam (CAZ-AVI) plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections (cIAIs) in hospitalized adults (2013-2015).
• 20. Randomized, double-blind, multicenter, phase III study to evaluate the immunogenicity and safety of ‘MG1109 (egg-based, pre-pandemic influenza (H5N1) vaccine)’ administered intramuscularly in healthy adult volunteers (2013-2014).
• 21. A phase III, multicenter, randomized, double-blind, comparative study to evaluate the efficacy and safety of ceftaroline fosamil (600 mg every 8 hours) versus vancomycin plus aztreonam in the treatment of patients with complicated bacterial skin and soft tissue infections with evidence of systemic inflammatory response or underlying comorbidities (2012 – 2015).
• 22. A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 50 years and older (Phase 3) (2011- 2015).
• 23. A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 70 years and older (Phase 3) (2011- 2015).

국제학술지(SCI/SCIE)

• 1. Safety and effectiveness of peramivir in Korean adult influenza patients: prospective observational study based on post-marketing surveillance data. J Kor Med Sci. 2018. 33(32)
• 2. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea. Human vacc immunother. 2018. 14(3): 587-592.
• 3. Clinical and economic analysis of the 2009 H1N1 influenza pandemic among pregnant Korean women. Kor J Int Med. 2017.
• 4. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Human vacc immunother. 2017. 13(7): 1653-1660.
• 5. Disease burden of 2013-2014 seasonal influenza in adults in Korea. Plos one. 2017. 12(3): e0172012.
• 6. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults. J Kor Med Sci. 2016. 31(1):13-17.
• 7. Suboptimal Effectiveness of the 2011-2012 Seasonal Influenza Vaccine in Adult Korean Population. Plos one. 2015. 10(3): e0098716
• 8. Immunity and the burden of herpes zoster. J Med Virol. 2014. 86(3): 525-530.
• 9. Severe influenza treatment guideline. Kor J Int Med. 2014. 29(1): 132-147.
• 10. Herpes zoster vaccine in Korea. Clin Exp Vac Res. 2013. 2(2): 92-96.
• 11. Case-control study of the effectiveness of the 2010-2011 seasonal influenza vaccine for prevention of laboratory-confirmed influenza virus infection in the Korean adult population. Clin Vac Imunol. 2013. 20(6): 877-881.
• 12. Clarithromycin and amikacin vs. clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: a prospective observational study. Clin Microbiol Infect. 2011. 17(8): 1084-1090.
• 13. Outbreak of measles in the Republic of Korea, 2007: Importance of nosocomial transmission. J Infect Dis. 2011. 204: S483-S490.
• 14. The Clinical usefulness of the SD Bioline Influenza Antigen Test for detecting the 2009 Influenza A (H1N1) virus. Yonsei Med J. 2011. 52: 683-685.
• 15. Fatal PD peritonitis, necrotizing fasciitis, and bacteremia due to Shewanella putrefaciens. Periton Dialysis Int. 2010. 30(6): 667-669.
• 16. Liver abscess and empyema due to Lactococcus lactis cremoris. J Kor Med Sci. 2010. 25(11): 1669-1671.
• 17. Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program. J Kor Med Sci. 2010. 25(7): 999-1004.
• 18. Seroprevalence of Varicella-Zoster virus in Korea. J Med Virol. 2010. 82: 2123-2126.
• 19. Disease burden of herpes zoster in Korea. J Clin Virol. 2010. 47: 325-329.
• 20. Are gastric acid suppressants a risk factor for enteric peritonitis. Periton Dialysis Int. 2008. 28(3): 236-237.
• 21. Appropriateness of antibiotic prophylaxis for major surgery in Korea. Infect Contr Hosp Epidemiol. 2007. 28:997-1002.
• 1. CAPD Peritonitis Due to Brevundimona svesicularis. Periton Dialysis Int. 2006. 26: 510-512.

국내학술지

• 1. Clinical presentation and outcomes of middle east respiratory syndrome in the Republic of Korea. Infect Chemother. 2016. 48(2): 118-126.
• 2. Spondylitis with an Epidural Abscess due to Mycobacterium fortuitum: A Case Report. Kor J Int Med. 2015. 88(6): 728-731.
• 3. Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014. Infect Chemother. 2015. 47(1): 68-79
• 4. Simultaneous chylothorax and chylous ascites due to tuberculosis. Infect Chemother. 2014. 46(1): 50-53.
• 5. Mycotic aneurysm of the aortic arch. Kor J Crit Car Med. 2014. 29: 231-233.
• 6. Clinical practice guideline for antiviral treatment and chemoprophylaxis of seasonal influenza. Infect Chemother. 2012. 44(4): 233-249.
• 7. A case of severe cholangitis caused by Rautella planticola in a patient with pancreatic cancer. Infect Chemother. 2012. 44(3): 210-212.
• 8. Clinical features on invasive pneumococcal disease in Korea. Infect Chemother. 2010. 42(3): 156-161.
• 9. The evaluation of policies on 2009 influenza pandemic in Korea. J Prev Med Public Health. 2010. 43(2): 105-108.
• 10. Clinical features of invasive pneumococcal disease in Korea. Infect Chemother. 2010. 42(3): 156-161.
• 11. Vaccine strategy for influenza A (H1N1) pandemic. Infect Chemother. 2009. 41(5): 259-264.
• 12. Immunization policy in Korea. Infect Chemother. 2008. 40(1): 14-23.
• 13. Persistent bacteremia and fungemia-risk factors and clinical significance. Kor J Med. 2007. 72(6): 647-657.
• 14. Epidemiology and clinical significance of bacteriuria caused by vancomycin-resistant enterococci. Infect Chemother. 2006. 38(5): 242-249.

Research Topic

Influenza

인플루엔자(influenza)는 매우 중요한 호흡기 바이러스 감염병이다. 매년 가을부터 이듬해 봄까지 유행하는 계절인플루엔자로 인해 전체 인구의 10-20%가 감염되어 사회경제적으로 상당한 질병부담을 유발할 뿐만 아니라 10-40년에 한 번씩 발생하는 대유행 인플루엔자는 국제적으로 심각한 보건상의 문제를 일으킨다. 따라서 인플루엔자에 대한 지속적인 감시, 연구 및 대비는 매우 중요하다. 최원석 교수는 인플루엔자의 질병부담, 인플루엔자 백신의 효과 평가, 항바이러스제 효과 평가 및 인플루엔자 관련 정책에 대한 연구를 수행하고 있다.

Herpes zoster

대상포진(herpes zoster)은 수두-대상포진 바이러스(herpes zoster virus, VZV)가 수두(varicella)의 형태로 초감염(primary infection)을 유발한 뒤, 신경절에 잠복(latent state)되어 있다가 연령 증가, 기저질환 등으로 인해 면역기능이 저하되면 재활성화(reactivation) 되어 발생하는 질환이다. 대상포진에 대한 여러 국가의 역학 연구에 따르면, 전체 인구의 1/3 정도는 평생 1회 이상 대상포진을 경험할 정도로 대상포진은 발생률이 높고, 대상포진 후 신경통(post-herpetic neuralgia, PHN) 등 합병증이 동반되는 경우가 많아 사회, 경제적으로 심각한 질병부담을 유발하는 것으로 알려져 있다. 최원석 교수는 대상포진의 질병부담, 대상포진 백신의 효과 평가 및 관련 정책에 대한 연구를 수행하고 있다.

Adult immunization

예방접종은 소아 뿐 아니라 성인에게도 매우 중요하다. 성인에게 권고되는 백신으로는 인플루엔자 백신, 폐렴사슬알균 백신, Td/Tdap 백신, 대상포진 백신 등이 있으며, 성인을 대상으로 한 새로운 백신이 계속 개발되고 있다. 최원석 교수는 성인예방접종과 관련된 지침 개발, 정책 설정, 백신 효과 평가 등 성인예방접종과 관련된 다양한 범위의 연구를 수행하고 있다.

Surveillance and control of infectious diseases

2002년 SARS, 2009년 신종인플루엔자, 2016년 MERS-CoV 유행 등 사람 간 전파가 가능한 감염질환으로 인한 공중보건학적 위기 상황은 예고 없이 지속적으로 발생한다. 뿐만 아니라, carbapenem-resistant A. baumannii (CRAB) 등 내성균에 의한 의료기관 내 문제도 매우 심각하다. 이러한 문제에 대응하기 위해서는 높은 수준의 감염감시 및 관리 시스템이 필수적으로 필요하다. 최원석 교수는 인플루엔자 감시체계(HIMM), 경기도 발열 감시 체계, MERS-CoV 환자 관리, 감염관리실을 통한 의료기관 내 감염관리의 경험을 바탕으로 더 나은 감염질환의 관리를 위한 연구를 수행하고 있다.

Clinical trials for new drugs or medical devices

새롭게 개발된 약물이나 의료기기가 임상에서 얼마나 안전하고 효과적인지 평가하는 일은 의료기술의 발달을 위해 필수적이다. 그러나 적절한 임상연구를 수행하기 위해서는 충분한 경험과 지원체계가 필수적으로 필요하다. 최원석 교수는 다양한 책임연구자로 1-3상에 이르는 다양한 임상시험을 수행한 바 있으며, 임상시험과 관련된 설계, 자문 등의 역할을 수행하고 있다.

Teaching for medical students of Korea University College of Medicine

고려대학교 의과대학 의학과의 감염학 강의, 안산병원 감염내과 폴리클(의과대학 실습학생)에 대한 교육 및 관리를 담당하고 있다.

담당강의: 위장관 감염 및 복강내 감염, 의료관련감염